Dr Alessio Cortellini is a consultant in medical oncology and a clinical scientist with a special interest in immunotherapy of cancer and lung cancer.
He graduated with honors at the University of L’Aquila in Italy, where he also completed his residency in medical oncology with full remarks and honors (July 2018) and his PhD program in experimental medicine with full remarks and honors (May 2022).
After leading the immunotherapy program at University of L’Aquila for more than a year he moved to London in 2020, where he worked in the early phase clinical trial unit at Imperial College London, under the supervision of Dr David J Pinato.
In July 2022 he moved to Rome, and he is now working as consultant medical oncologist and assistant professor of medicine at the Fondazione Policlinico Universitario Campus Bio-Medico and Campus Bio-Medico University. However, given the fruitful collaboration and the number of high-level research goals achieved during his fellowship, he is keeping his honorary academic post as Clinical Lecturer at Imperial College London.
Since February 2022 Alessio holds the National Scientific Qualification issued by the Italian Ministry of Education, University and Research as associate professor (section of Oncology, Hematology and Rheumatology).
The focus of Dr Cortellini’s research is represented by the study of clinic-pathologic predictors for cancer immunotherapy, with a special interest in lung cancer, host factors and immune-related adverse events. His clinical and research expertise in this field have been widely recognized.
Alessio has been awarded the Third Annual Young Investigator Award 2020, by the editors of The Oncologist, and in 2021 he has bee awarded the Journal for ImmunoTherapy of Cancer (JITC) Best Clinical/Translational Cancer Immunotherapy Paper Award, selected by the Society for Immunotherapy of Cancer (SITC).
Alessio’s capacity for networking is immense. As a result, he has coordinated several multi-center studies, mainly through a genuine spirit of productive interaction with other young colleagues internationally.
At 38 years he has authored/co-authored more than 190 papers in recognized journals (including papers as first/last author on the Lancet Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, JAMA Oncology, Annals of Oncology, Journal for Immunotherapy of Cancer, Journal of the National Cancer Institute, European Journal of Cancer).
Alessio is also associate editor for the Journal of Translational Medicine of the BMC Part of Springer Nature editorial group.
et al., 2023, The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients., Exp Dermatol
et al., 2023, Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma., Hepatol Int, Vol:17, Pages:904-914
et al., 2023, Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium., J Clin Oncol, Vol:41, Pages:3712-3723
et al., 2023, Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer, Clinical Cancer Research, Vol:29, ISSN:1078-0432, Pages:2714-2724